Krishnan, A., Pasquini, M., Blackwell, B., Knust, K., Bashey, A., Devine, S., … Stadtmauer, E. (2017). Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance. In Clinical Lymphoma Myeloma and Leukemia (Vol. 17, pp. e5–e5). Elsevier BV. https://doi.org/10.1016/j.clml.2017.03.009

Krishnan, Amrita, Marcelo Pasquini, Beth Blackwell, Kristin Knust, Asad Bashey, Steven Devine, Yvonne Efebera, et al. “Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance.” In Clinical Lymphoma Myeloma and Leukemia, 17:e5–e5. Elsevier BV, 2017. https://doi.org/10.1016/j.clml.2017.03.009.

Krishnan A, Pasquini M, Blackwell B, Knust K, Bashey A, Devine S, et al. Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. e5–e5.

Krishnan, Amrita, et al. “Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance.” Clinical Lymphoma Myeloma and Leukemia, vol. 17, no. 1, Elsevier BV, 2017, pp. e5–e5. Crossref, doi:10.1016/j.clml.2017.03.009.

Krishnan A, Pasquini M, Blackwell B, Knust K, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Giralt S, Parameswaran H, Horowitz M, Koreth J, Landau H, McCarthy P, McClune B, Nelson C, Qazilbash M, Shah N, Vesole D, Vij R, Vogl DT, Somlo G, Stadtmauer E. Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2017. p. e5–e5.